• 1H FY25 revenue expected to be $210 - $215 million, up 12 - 14% on 1H FY24
• 1H FY25 underlying EBITDA expected to be $30 - $32 million, up 275 - 300% on 1H FY24
• Continued growth in Women's Health portfolio and improved Dermatology margins

Mayne Pharma Group Limited (ASX: MYX) has provided a market update for the six months ended 31 December 2024 (1H FY25). The company expects 1H FY25 revenues to be $210 - $215 million, reflecting 12 - 14% growth on the prior corresponding period (1H FY24). Mayne Pharma also expects to report 1H FY25 underlying EBITDA of $30 - $32 million, representing growth of 275 - 300% on 1H FY24. This strong underlying EBITDA result is driven by continued growth across the Women's Health portfolio with increased operating leverage, as well as improved margins in the Dermatology segment primarily through product mix. The company's performance since the update provided at the annual general meeting on 21 November 2024 is expected to be reflected across the entire half-year period. Looking ahead to 2H FY25, Mayne Pharma expects to see continued growth, some seasonal cost impacts from patient payment programs, and an increase in promotional expenses for Women's Health products to drive additional growth. Cash and marketable securities at 31 December 2024 were $124.9 million, a decrease of $4.6 million compared to the balance as of 31 October 2024 due to the timing of GTN payments.

Mayne Pharma expects 1H FY25 revenues to be $210 - $215 million, reflecting 12 - 14% growth on 1H FY24. The company also expects to report 1H FY25 underlying EBITDA of $30 - $32 million, representing growth of 275 - 300% on 1H FY24.

Mayne Pharma expects to see continued growth in 2H FY25, with some seasonal cost impacts from patient payment programs and an increase in promotional expenses for Women's Health products to drive additional growth.